Author

P. Corradini

h-index 15 View on Semantic Scholar

We have 3 of 96 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

SC forimtamig demonstrated potent and durable activity in RRMM, which could be enhanced with a condensed step-up schedule, highlighting the narrow therapeutic window for GPRC5D as a target for T-cell-engaging bispecific antibodies.

Anna Caroline Hasselbalch, Simon J. Harrison, Salomon Manier et al. · Blood Advances · 0 citations

Open access Sep 2026

Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies.

Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD19 has demonstrated efficacy as salvage treatment for patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL), however, a direct comparison between CAR T activity and other salvage treatments has not previously been performed. This s...

A. Guidetti, I. Dogliotti, A. Chiappella et al. · Haematologica · 0 citations

Open access Sep 2026

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these ch...

I. Dekhtiarenko, Jan Attig, I. Lelios et al. · Blood Advances · 0 citations